Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors-Reference-Cited by-同舟云学术

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Published:2020-09-24 Issue:22 Volume:80 Page:4986-4997
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Sootome Hiroshi,Fujita Hidenori,Ito Kenjiro,Ochiiwa Hiroaki,Fujioka Yayoi,Ito Kimihiro,Miura Akihiro,Sagara Takeshi,Ito Satoru,Ohsawa Hirokazu,Otsuki Sachie,Funabashi Kaoru,Yashiro Masakazu^ORCID,Matsuo Kenichi,Yonekura Kazuhiko,Hirai Hiroshi

Funder

Taiho Pharmaceutical

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of new drugs approved by EMA during 2023;European Journal of Medicinal Chemistry;2024-11

2. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

3. Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-11

4. LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics;Biomedical Chromatography;2024-09-05

5. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib;Clinical and Translational Science;2024-09